Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: April 2007
-
By Donald Zuhn — In an eagerly awaited decision regarding the Federal Circuit’s "teaching, suggestion, or motivation" (TSM) test for analyzing obviousness, the Supreme Court on Monday issued its ruling in KSR Int’l Co. v. Teleflex Inc. In a 24-page opinion, the Court reversed the Federal Circuit’s determination of validity with respect to…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Wyeth v. Osmotica Pharmaceutical Corp.7:07-cv-00067; filed April 20, 2007 in the Eastern District of North Carolina Infringement of U.S. Patent Nos. 6,403,120…
-
May 6-9, 2007 – BIO International Convention – Boston, MA May 9, 2007 – "Frontiers in Stem Cell Biology" (University of Michigan Life Sciences Institute) – Ann Arbor, MI June 26-28, 2007 – Euro-Biotech Forum 2007 – Paris, France
-
By Donald Zuhn — On Thursday, CEL-SCI Corporation announced that it had been granted U.S. Patent No. 7,199,216 by the U.S. Patent & Trademark Office. The ‘216 patent relates to conjugated peptides in which an antigenic peptide that is associated with an immune disorder is covalently bonded to a T-cell binding ligand that…
-
By Kevin E. Noonan — The sanctimony continues over the U.S. Patent and Trademark Office re-examination of the Thomson stem cell patents. This time, it is an article by Constance Holden in the April 13, 2007 issue of Science. Although refreshingly factual, it manages in ways both frank and subtle to create the…
-
By Christopher P. Singer — In an April 26, 2007 press release SciClone Pharmaceuticals Inc. announced that it acquired exclusive rights in the U.S. and Canada to develop and commercialize a compound in the clinical stage for treatment of pancreatic cancer. The drug, RP101, was brought to Phase I clinical trials as a…
-
By Donald Zuhn — Bristol-Myers Squibb Co. and Pfizer Inc. announced today that the companies will be entering into two separate collaborations. In the first, the two companies will be working together to develop and commercialize Bristol-Myers Squibb’s anticoagulant, apixaban. In the second, the collaboration will focus on the research, development, and commercialization…
-
By Kevin E. Noonan — The end of the consolidated omeprazole litigation may have been reached this week, when the Federal Circuit ruled on AstraZeneca’s appeal over the validity of U.S. Patent No. 6,013,281. In its decision, the Court majority (Judges Rader and Bryson) upheld the District Court’s finding that the ‘281 patent…
-
By Christopher P. Singer — Luminex Corporation announced that it received a non-exclusive license from Johns Hopkins University with rights to use the University’s patented cystic fibrosis (CF) genetic markers. CF is a chronic autosomal recessive disorder affecting the lungs and digestive tract caused by mutations in the cystic fibrosis transmembrane conductance regulator…
-
By Jason Derry — Cytos Biotechnology AG has granted a worldwide, exclusive license to Novartis to develop, manufacture, and commercialize its therapeutic vaccine for nicotine addiction, CYT002-NicQb. The vaccine is currently in Phase II clinical development. Cytos may receive upfront and milestone payments, as well as royalty payments, based on the successful commercial…
Patent Docs 